+34 620 10 75 37info@nanbiosis.com

Nanbiosis

‘Point-of-care or PoC’ devices are able to directly detect the genetic material of the virus in just 30 minutes

Twenty five Spanish researchers linked to the Higher Center for Scientific Research, CSIC, who are working more directly on the project ‘Point-of-care tests for the rapid detection of SARS-CoV-2’ – Studies for the development of technologies effective diagnosis and early detection of SARS-CoV-2- have met since last Wednesday and until this Friday at the Benasque Science Center ‘Pedro Pascual’ to analyze the state or of the different programs and lines of research on the covid-19.

After months of intense work, among the most outstanding achievements in relation to the detection of the genetic material of the virus, is the development of a series of technologies that allow this detection without the need for PCR. Researchers have managed, by designing specific probes, to directly detect the genetic material of the virus in just 30 minutes.

Dra. Pilar Marco, researchar of CSIC and Scientific Director of Nanbiosis U2 Custom Antibody Service (CAbS) – explains that “the PCR technique, which it is very sensitive and very precise, has a disadvantage in terms of time because it requires an amplification stage of this genetic material that makes the process long, this is going to revolutionize the diagnosis, not only for Covid-19, but also of other infectious diseases”.

Researcher of three units of NANBIOSIS, attended the meeting and some of them gave talks:

  • Nuria Pascual, Scientific Coordinator of NANBIOSIS U2 CAbS espoke about Antibodies production
  • Also from NANBIOSIS Unit 2, J. Pablo Salvador espoke about Immunochemical tests and .
  • Serological test of peptide epitopes were explained by Julian Guercetti.
  • Anna Avigñó, Scientific Coordinator of NANBIOSIS U29, espoke about Design of oligonucleotides for a new method in Covid-19 detection without PCR.
  • And Macarena Duran, representing MS4N group and the Peptide synthesis unit of NANBIOSIS (U3) explained the synthesis of potential SARS-COV2 epitopes that have been applied for hybridome selection for mAb and to generate epitope microarrays to analyze serological samples.

The meeting has served to share the most relevant results that have been obtained in the context of the project, as well as discussion of new strategies to address problems that have arisen throughout the project and in turn, discuss future objectives.

Other related news by NANBIOSIS:

Source of information: Heraldo de Aragón

Read More

Vaccines against Covid, biomedical signal processing for sleep disorders and regenerative medicine, at the XV CIBER-BBN Annual Conference

The CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) will hold its XV Annual Congress, which will be held online for another year, on November 15 and 16. The conference will begin with a welcome that will be given by Cristóbal Belda, director of the ISCIII, and the scientific director of CIBER-BBN Ramón Martínez Máñez, and will aim to share advances in research in bioengineering, biomaterials and nanomedicine, in addition to advancing synergies with other disciplines and institutions.

This year’s edition will include three plenary talks given by internationally recognized experts in the fields of SARS-CoV-2 infection and vaccination, biomedical signal processing for sleep disorders, and regenerative medicine and biosensors.

In addition to a selection of internal collaborations, valorization projects and collaboration with the CIBER de Cáncer (CIBERONC), the CIBER-BBN researchers will be able to know first-hand the three programs of the Precision Medicine Infrastructure (IMPaCT) and the perspectives of NANBIOSIS ICTS.

Likewise, there will also be time to highlight the best works of young researchers in recognition of the best publications of 2020 with CIBER-BBN member authors under 30 years of age.

Access to the broadcast talks and subsequent debate is free after registering for the event at this link: https://jornadasanuales.ciber-bbn.es/

Read More

Colloidal nanocrystals for energy applications

Semiconductors are materials used in a wide ranfe of applications since they are capable of capturing light and allowing us to take advantage of it. In addition, if we reduce its size to the nanometric scale we can activate additional very interesting properties

On October 16, “Technoscience and Energy” took place in Inseec, Lyon (France), a science-industry transfer event between French and Spanish companies and researchers from the energy sector in France. Among the invited speakers was María Bernechea Navarro, ARAID Investigator, at the Institute of Nanoscience and Materials of Aragon at University of Zaragoza-INMA.

In her talk, entitled “COLLOIDAL NANOCRYSTALS FOR ENERGY APPLICATIONS”, María Bernechea showed the development of nanomaterials stabilized in solution (to facilitate working with them), composed of abundant and non-toxic elements, as well as their use in various applications related to clean energy.

“We synthesize colloidal nanosemiconductors that are used for different applications. We mainly use these nanomaterials to harvest solar light and convert it into electrical current (solar cells) or remove pollutants in wastewater (using the materials as photocatalysts). More recently we have started to study the incorporation of these materials on carbon supports to fabricate electrodes that can be used in electrochemical storage devices (batteries or supercapacitors). These nanosemiconductors are fabricated at the NANBIOSIS U9 Synthesis of Nanoparticles Unit of CIBER-BBN and the INMA”, has explained María.

Last October 29, María Bernechea gave also a talk at the Faculty of Sciences of La Coruña entitled, “Colloidal Nano-Semiconductors for solar cells and other applications” that is avalilable in youtube. Dr. Bermechea expressly thanked the access to the ICTS NANBIOSIS for the development of these semiconductors.

Article of reference: Aina, S., Villacampa, B., Bernechea, M., Earth-abundant non-toxic perovskite nanocrystals for solution processed solar cells, Mater. Adv., 2021, 2, 4140 [DOI]

Read More

Nanobodies for biosening at the European Biosensor Symposium digital seminars

Next November 8, the researcher of NANBIOSIS U2 Custom Antibody Service (CAbS)  J.-Pablo Salvador will host the Seminar “Nanobodies for biosensing” in the framework of European Biosensor Symposium digital seminar series which are schedulled on the third Tuesday of every month.

Nanobodies® (Nbs) are the recombinant binding domain from the heavy chain antibodies tipically produced from camèlids.  Besides their great potential as molecules in drug development, Nanobodies possess excellent functional properties that aid in their development for diagnostic tools. In this seminar, Dr. Salvador will explain the the outstanding properties of Nanobodies. Three graduate student speaker and up to five graduate student poster presenters will will take the opportunity to show different applications in the biosensing area.

The online event will take place on 16th November at 18:00 

Registration is free.

Further information on the European Biosensor Symposium digital seminars

Read More

Dr Ramón Mangues, new member of the Royal Academy of Pharmacy of Catalonia

Dr. Ramon Mangues, head of the Oncogenesis and Antitumor Group and Scientific Director of NANBIOSIS U18 Nanotoxicology Unit of CIBER-BBN at the Sant Pau Research Institute, has been recently elected as a new member of the Royal Academy of Pharmacy of Catalonia.

The celebration will take place on November 8 at 7 pm, at the headquarters of the RAFC, (Royal Academy of Pharmacy of Catalonia) which was the headquarters of the old Hospital de la Santa Cruz since the 15th century, located at Calle del Hospital, 56, in Barcelona.

During the event, Dr. Mangues will read his admission speech “Selective delivery of drugs to metastatic stem cells“, which can be followed by zoom and live on Youtube using the following links:

Read More

NANBIOSIS U6 opens its doors to students of Nanoscience and Nanotechnology Degree at UAB

NANBIOSIS U6, Biomaterial Processing and Nanostructuring Unit from CIBER-BBN and ICMAB-CSIC, has received today the visit of students of the 4th year degree in Nanoscience and Nanotechnology of the Auonomous University of Barcelona.

During this visit, the students had the opportunity to get known of the facilities of Unit 6 of NANBIOSIS ICTS and the to work in a research laboratory. José Amable Bernabé has, Technical Coordinator of the unit, has shown the students the equipment for processing materials with compressed fluids and also some equipment for the characterization of particulate materials.

In the Degree in Nanoscience and Nanotechnology at the UAB, students prepare to synthesize, characterize and study the properties of materials at the nanoscale; to manipulate instruments and materials of test laboratories for the study of phenomena at the nanoscale and to interpret the data obtained through experimental measurements.

Unit 6 at ICMAB-CSIC is focussec on the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. It is part of the Unique Scientific and Technical Infracstructure “NANBIOSIS”

Read More

CIBER renews its ISO 9001: 2015 Quality Certificate for its Management System

CIBER | October 14, 2021

CIBER, the main partner of NANBIOSIS obtained, last month, the ISO 9001: 2015 accreditation, issued by the ENAC (National Accreditation Entity) through TÜV Rheinland Ibérica Inspection, Certification and Testing SA, by which the quality in the CIBER management system is certified.

The scope of the quality management system defined in the certificate covers: “Staff and training management services, administrative accounting and communication management services for the Center for Biomedical Research on the Net”.

CIBER keeps updated the Quality Management System (QMS) designed to continuously improve the effectiveness and efficiency of performance, through the consideration of the needs of the interested parties, and to increase the satisfaction perceived by its clients. .

The CIBER obtained, in September 2021, the ISO 9001: 2015 accreditation, issued by the ENAC (National Accreditation Entity) through TÜV Rheinland Ibérica Inspection, Certification and Testing SA, by which the quality in the CIBER management system.

The scope of the quality management system defined in the certificate covers: “Personnel and training management services, administrative accounting and communication management services for the Center for Biomedical Research on the Net”.

The CIBER keeps updated the Quality Management System (QMS) designed to continuously improve the effectiveness and efficiency of performance, through the consideration of the needs of the interested parties, and to increase the satisfaction perceived by its clients. .

All the documented information related to the Quality Management System (QMS) implemented in CIBER, as well as the “Quality Manual” document are available in the “Document Manager” section of the CIBER Intranet. Likewise, the CIBER “Quality Policy” can be consulted on the Transparency Portal of the Web.

Read More

ISO 9001-2015 Quallity Management Certification for NANBIOSIS U12

NANBIOSIS U12 “Nanostructured liquid characterization unit” of IQAC-CSIC and CIBER-BBN, led by Dr. Carlos Rodriguez Abreu and D. Jordi Esquena, has implemented a Quality Management System for the scope of Technological service for characterization of colloidal dispersions, which fulfills the requirements of the standard ISO 9001:2015. An IQNet recognized certificate has been issued by AENOR last week.

This certification will expand and consolidate the service  that Unit 12 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration in cooperative international projects.

The ISO 9001 Standard is the most widespread Quality Management tool worldwide, with over one million certificates in 175 countries. The main objective of the standard is to increase customer satisfaction through continuous improvement processes. It is designed so that the organizations that apply it can guarantee their ability to offer services that meet the requirements of their customers. This international standard promotes the adoption of a process-based approach when the effectiveness of a quality management system is developed, implemented and improved, based in turn on the PDCA (Plan, Do, Check, Act) continuous improvement cycle.

The main benefits derived from ISO 9001 certification for organizations are: systematization of operations, improvement of internal organization, generation of a higher level of confidence in the internal and external environment, increased competitiveness, guarantee of compliance with legislation and regulations related to products and services, among others

Read More

Pablo Laguna talking about Physiologically driven biomedical signal processing at the Autonomous University of San Luis Potosí

Zaragoza, October 14th, 2021 Bsicos.i3a.es

Pablo Laguna, Scientific Director of NANBIOSIS U27 High Performance Computing and researcher of BSICoS Group of I3A-UNIZAR and CIBER-BBN gave a talk about Physiologically driven biomedical signal processing at the Faculty of Physics at the Autonomous University of San Luis Potosí (UASLP) in Mexico. He explaned how biomedical signals convey information about biological systems and can emanate from sources of as varied origins as electrical, mechanical or chemical.

In particular, biomedical signals can provide relevant information on the function of the human body. This information, however, may not be apparent in the signal due to measurement noise, presence of signals coming from other interacting subsystems, or simply because it is not visible to the human eye. Signal processing is usually required to extract the relevant information from biomedical signals and convert it into meaningful data that physicians can interpret. In this respect, knowledge of the physiology behind the biomedical measurements under analysis is fundamental. Not considering the underlying physiology may lead, in the best case, to processing methods that do not fully exploit the biomedical signals being analyzed and thus extract only partially their meaningful information and, in the worst case, to processing methods that distort or even remove the information of interest in those signals.

Biomedical Signal Processing (BSP) tools are typically applied on just one particular signal recorded at a unique level of the functional system under investigation and with limited knowledge of the interrelationships with other components of that system. In most instances though, BSP can benefit from an analysis in which more than one signal is evaluated at a time (multi-modal processing), different levels of function are considered (multi-scale processing) and scientific input from different disciplines is incorporated (multi-disciplinary processing). For each problem at hand, the BSP researcher should decide up to which extent information from a number of signals, functional levels or disciplines needs to be incorporated to solve the problem.

As an example, a multi-scale model may be necessary in cases where, for instance, a deeper knowledge of the cell and tissue mechanisms underpinning alterations in a body surface signal is required, whereas a simplified single-scale model may be sufficient in other cases, as when investigating the relationship between two signals measured on the whole human body. At present, there are many biomedical signals that can be acquired and processed using relatively low-cost systems, which makes their use in the clinics very extensive. In particular, non-invasive signals readily accessible to physicians are increasingly being used to improve the diagnosis, treatment and monitoring of a variety of diseases. The presentation aims to illustrate the role played by BSP in the analysis of cardiovascular signals. A set of applications will be presented where BSP contributes to improve our knowledge on atrial and ventricular arrhythmias, the modulation of cardiac activity by the autonomic nervous system (ANS) and the interactions between cardiac and respiratory signals.

Read More

Results of the POSITION-II Project “A pilot line for the next generation of smart catheters and implants”

Cáceres, October 14th, 2021

POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA.

It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters and implants by the introduction of open technology platforms for: miniaturization, in-tip AD conversion, wireless communication, MEMS transducer technology and encapsulation. These platforms are open to multiple users and for multiple applications.

POSITION II will enable the further development of the European R&D and manufacturing capability, not only encompassing the micro-fabricated device itself, but also the various value chains that they enable. Finally, by bringing smart catheters into the domain of high volume manufacturing, POSITION II will improve the quality of health-care at manageable cost.

The project, led by Philips Electronics Netherlands B.V, has been developed by 45 partners located in 12 different countries and has finished in September 2021. Within this large collaborative project, the NANBIOSIS units at CCMIJU have been involved in the validation of a novel catheter to administer encapsulated cell therapy to the heart. Also NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU , has participated being responsible for carrying out the formulation of the cells in hydrogels, for administration through the catheter at the cardiac level, for the regeneration of heart tissue.

The results of the project are available on a video-format documentary that contains short interviews to the consortium partners on their participation. Specifically, CCMIJU has presented its work and results through a short interview to Dr. Verónica Crisóstomo, Coordinator of Cardiovascular Unit. The documentary can be found at https://vimeo.com/604674309/bd8b94050c

Further info about the project here: http://position-2.eu/

Read More